Clinical Implications of Amylin and Amylin Deficiency

The Diabetes Educator

Volumn 25, Issue 3, 1999, Pages 389-397

  Kruger, Davida F ^a   Gatcomb, Patricia M ^b   Owen, Susan K ^c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b YALE UNIVERSITY   (United States)

^c Grand Rapids Associated Internists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; ANTIDIABETIC AGENT; INSULIN; PRAMLINTIDE;

BLOOD; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

AMYLOID; BLOOD GLUCOSE; DIABETES MELLITUS; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0033130649     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572179902500310     Document Type: Article

References (41)

1. Wallum BJ, Kahn SE, McCulloch DK, Porte D Jr. Insulin secretion in the normal and diabetic human. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. Chichester, England: John Wiley & Sons; 1992;285-301.
2. Porte D Jr., Kahn SE. The key role of islet dysfunction in type II diabetes mellitus. Clin Invest Med. 1995;18:247-254.
3. Leahy JL. Natural history of β-cell dysfunction in NIDDM. Diabetes Care. 1990;13:992-1010.
4. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM. Purification and characterization of a peptide from amyloid-rich pancreases of type II diabetic patients. Proc Natl Acad Sci USA. 1987;84:8628-8632.
5. Moore CX, Cooper GJS. Co-secretion of amylin and insulin from cultured islet 1-cells, modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun. 1991;179:1-9.
6. Rink TJ, Beaumont K, Koda J, Young A. Structure and biology of amylin. Trends Pharmacol Sci. 1993;14:113-118.
7. Koda JE, Fineman MS, Kolterman OG, Caro JF. 24-hour plasma amylin profiles are elevated in IGT subjects vs. normal controls [abstract]. Diabetes. 1995;44(suppl 1):238A-238A.
8. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet. 1992;339:1179-1180.
9. Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE. Amylin response following Sustacal ingestion is diminished in type II diabetic patients treated with insulin [abstract]. Diabetologia. 1996;39(suppl 1):A149-A149.
10. Lefebvre PJ. Glucagon and its family revisited. Diabetes Care. 1995;18:715-730.
11. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia. 1995;38:642-648.
12. Ferrannini E, DeFronzo RA. Insulin actions in vivo: glucose metabolism. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. Chichester, England: John Wiley & Sons; 1992:409-438.
13. Kolterman OG, Gottlieb A, Moyses C, Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care. 1995;18:1179-1182.
14. Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997;40:82-88.
15. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41:577-583.
16. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care. 1996;19:468-471.
17. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med. 1992;33:1496-1500.
18. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:130-131.
19. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology. 1995;109:755-765.
20. Nowak TV, Johnson CP, Kalbfleisch JH, et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut. 1995;37:23-29.
21. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes: relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest. 1984;74:985-991.
22. Young A, Gedulin B, Jodka C, Green D. Insulin-induced hypoglycemia reverses amylin inhibition of gastric emptying in rats [abstract]. Diabetes. 1996;45(suppl 2):187A-187A.
23. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia. 1995;38:337-343.
24. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. J Clin Invest. 1986;77:1525-1532.
25. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism. 1997;46:67-70.
26. Fineman M, Koda J, Kolterman O. Subcutaneous administration of a human amylin analogue suppresses postprandial plasma glucagon concentrations in type I diabetic patients [abstract]. Diabetes. 1998;47(suppl 1):89A-89A.
27. Fineman M, Organ K, Kolterman O. The human amylin analogue pramlintide suppressed glucagon secretion in patients with type 2 diabetes [abstract]. Paper presented at: 34th Annual Meeting of the European Association for the Study of Diabetes; September 8-12, 1998; Barcelona, Spain. Abstract 653.
28. Hwang JH, Perseghin G, Rothman DL, et al. Impaired net hepatic glycogen synthesis in insulin dependent diabetic subjects during mixed meal ingestion: a 13C nuclear magnetic resonance spectroscopy study. J Clin Invest. 1995;95:783-787.
29. Orskov L, Alberti KGMM, Mengel A, et al. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1991;34:521-526.
30. Edelman SV, Kruger DF. A new look at glucose control. Practical Diabetol. 1997;16:9-13.
31. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
32. Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1415-1427.
33. Janes S, Gaeta L, Beaumont K, Beeley N, Rink T. The selection of pramlintide for clinical evaluation [abstract]. Diabetes. 1996;45(suppl 2):235A-235A.
34. Redalieu E, Thompson RG, Dean E. et al. Pharmacokinetics of pramlintide and free insulin following combined or separate injections in patients with type I diabetes [abstract]. Diabetes. 1996;45(suppl 2):220A-220A.
35. Kolterman OG, Schwartz S, Corder C, et al. Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996;39:492-499.
36. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabetic Med. 1997;14:547-555.
37. Thompson RG, Pearson L, Kolterman OG. Effect of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia. 1997;40:1278-1285.
38. Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM. Results of a multicenter trial. Diabetes. 1997;46:632-636.
39. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG, and the Pramlintide in Type 2 Diabetes Group. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care. 1998;21:987-993.
40. Rosenstock J, Whitehouse F, Schoenfeld S, Dean E, Blonde L, Kolterman O. Effect of pramlintide on metabolic control and safety profile in people with type 1 diabetes [abstract]. Diabetes. 1998;47(suppl 1):88A-88A.
41. Ratner R, Levetan C, Schoenfeld S, Organ K, Kolterman O. Pramlintide therapy in the treatment of insulin-requiring type 2 diabetes: results of a 1-year placebocontrolled trial [abstract]. Diabetes. 1998;47(suppl 1):88A-88A.